Department of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Biochem J. 2018 Jun 26;475(12):2057-2071. doi: 10.1042/BCJ20180238.
Inositol-1,4,5-trisphosphate 3-kinase-A (ITPKA) exhibits oncogenic activity in lung cancer cells by regulating Ins(1,4,5)P-mediated calcium release and cytoskeletal dynamics. Since, in normal cells, ITPKA is mainly expressed in the brain, it is an excellent target for selected therapy of lung cancer. However, ITPKB is strongly expressed in normal lung tissues, but is down-regulated in lung cancer cells by miR-375, assuming that ITPKB might have tumor suppressor activity. In addition, ITPKB binds to F-actin making it likely that, similar to ITPKA, it controls actin dynamics. Thus, the treatment of ITPKA-expressing lung cancer with ITPKA inhibitors simultaneously inhibiting ITPKB may counteract the therapy. Based on these considerations, we analyzed if ITPKB controls actin dynamics and if the protein reduces aggressive progression of lung cancer cells. We found that ITPKB bundled F-actin in cell-free systems. However, the stable expression of ITPKB in H1299 lung cancer cells, exhibiting very low endogenous ITPKB expression, had no significant effect on the actin structure. In addition, our data show that ITPKB negatively controls transmigration of H1299 cells by blocking Ins(1,4,5)P-mediated calcium release. On the other hand, colony formation was stimulated by ITPKB, independent of Ins(1,4,5)P-mediated calcium signals. However, dissemination of H1299 cells from the skin to the lung in NOD scid gamma mice was not significantly affected by ITPKB expression. In summary, ITPKB does not affect the cellular actin structure and does not suppress dissemination of human lung cancer cells in mice. Thus, our initial hypotheses that ITPKB exhibits tumor suppressor activity could not be supported.
肌醇-1,4,5-三磷酸 3-激酶-A(ITPKA)通过调节 Ins(1,4,5)P 介导的钙释放和细胞骨架动力学,在肺癌细胞中表现出致癌活性。由于 ITPKA 在正常细胞中主要在大脑中表达,因此它是肺癌选择性治疗的理想靶点。然而,ITPKB 在正常肺组织中强烈表达,但被 miR-375 下调,假设 ITPKB 可能具有肿瘤抑制活性。此外,ITPKB 与 F-肌动蛋白结合,使其可能像 ITPKA 一样,控制肌动蛋白动力学。因此,用 ITPKA 抑制剂治疗表达 ITPKA 的肺癌,同时抑制 ITPKB,可能会对抗治疗。基于这些考虑,我们分析了 ITPKB 是否控制肌动蛋白动力学,以及该蛋白是否降低肺癌细胞的侵袭性进展。我们发现 ITPKB 在无细胞系统中捆绑 F-肌动蛋白。然而,在 H1299 肺癌细胞中稳定表达 ITPKB,其内源性 ITPKB 表达水平非常低,对肌动蛋白结构没有显著影响。此外,我们的数据表明,ITPKB 通过阻断 Ins(1,4,5)P 介导的钙释放来负调控 H1299 细胞的迁移。另一方面,ITPKB 独立于 Ins(1,4,5)P 介导的钙信号刺激集落形成。然而,ITPKB 表达并未显著影响 H1299 细胞从皮肤向肺部的播散。总之,ITPKB 不会影响细胞肌动蛋白结构,也不会抑制人肺癌细胞在小鼠中的播散。因此,我们最初的假设,即 ITPKB 表现出肿瘤抑制活性,不能得到支持。